Back

Reduction in total cardiovascular events with evolocumab in patients with no prior myocardial infarction or stroke: a pre-specified analysis of VESALIUS-CV

29 August 2026 (15:10 - 15:20)
Organised by: Logo
Congress Presentation Part of: Lipid lowering in the prevention era: from statins to RNA therapeutics Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Jose Carlos Nicolau

Heart Institute of the University of Sao Paulo (InCor), Sao Paulo (Brazil)

5 More presentations in this session

Presentation thumbnail
The clinical benefits of immediate versus delayed use of PCSK9 inhibitors for patients with established atherosclerotic cardiovascular disease in the UK
Professor K. Ray (London, GB)
Abstract
Presentation thumbnail
Alirocumab and cardiovascular outcomes in patients without a prior ischemic event
Assistant Professor M. Leening (Rotterdam, NL)
Abstract
Presentation thumbnail
Potent and sustained blood pressure reduction with a novel small interfering RNA targeting hepatic angiotensinogen: results from a first-in-human, randomised, phase 1 study
Doctor M. Yang (Chengdu, CN)
Abstract
Presentation thumbnail
Real-world comparative outcomes of evolocumab versus high-intensity statin for primary prevention
Doctor A. Ajibade (Iowa City, US)
Abstract
Presentation thumbnail
Association of cancer incidence and cancer mortality with statins, ezetimibe, and statin–ezetimibe therapy: a pairwise and bayesian network meta-analysis of randomized controlled trials
Doctor S. Saluja (New Delhi, IN)
Abstract

Access the full session

Session thumbnail
Lipid lowering in the prevention era: from statins to RNA therapeutics

The Event

Event poster

ESC Congress 2026

29 August 2026 15:10 CET
You may be interested in
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors treatment on acute coronary syndrome and stroke incidence: a metanalysis of currently available clinical trials
3 September 2019
thumbnail
Congress Presentation
LDL-C reduction and residual cardiovascular risk in heterozygous familial hypercholesterolemia: a matched cohort study in South Wales
1 September 2025
thumbnail
Congress Presentation
Incidence of cardiovascular events in patients with atrial fibrillation anticoagulated with rivaroxaban after 2.5 years of follow-up: not all is stroke or bleeding
27 August 2021
thumbnail
Congress Session
Before the first missed beat: addressing LDL-C management before an event
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources